Vinorelbine and interferon-α2c as second-line therapy in metastatic renal cell carcinoma

Anti-Cancer Drugs

Volumn 11, Issue 3, 2000, Pages 175-179

  Schmidinger, Manuela ^a   Steger, Günther G ^a   Budinsky, Alexandra C ^a   Wenzel, Catharina ^a   Brodowicz, Thomas ^a   Locker, Gottfried J ^a   Kramer, Gero ^a   Marberger, Michael ^a   Zielinski, Christoph C ^a,b,c  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

Interferon; Renal cell carcinoma; Second line; Vinorelbine

Indexed keywords

ALPHA2 INTERFERON; ALPHA2C INTERFERON; NAVELBINE; ONDANSETRON; PARACETAMOL; ANTINEOPLASTIC AGENT; BIOLOGICAL RESPONSE MODIFIER; DRUG DERIVATIVE; VINBLASTINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; EDEMA; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; KIDNEY CARCINOMA; LEUKOPENIA; LUNG DISEASE; MALE; METASTASIS; NAUSEA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; VOMITING; AUSTRIA; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; SALVAGE THERAPY; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AUSTRIA; BIOLOGICAL RESPONSE MODIFIERS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; IMMUNOTHERAPY; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2C; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINBLASTINE;

EID: 0033625243     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200003000-00005     Document Type: Article

References (24)

1. 1. Canobbio L, Miglietta L, Boccardo F. Medical treatment of advanced renal cell carcinoma: present options and future directions. Cancer Treat Rev 1996; 22: 85-104.
2. 2. Dexeus FH, Logothetis CJ, Sella A, et al. Circadian infusion of floxuridine in patients with metastatic renal cell carcinoma. J Urol 1991; 146: 709-13.
3. 3. Hartmann JT, Bokemeyer C. Chemotherapy for renal cell carcinoma. Anticancer Res 1999; 19: 1541-3.
4. 4. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial [see comments]. Lancet 1999; 353: 14-7.
5. 5. Henriksson R, Nilsson S, Colleen S, et al. Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen [see comments]. Br J Cancer 1998; 77: 1311-7.
6. 6. Steineck G, Strander H, Carbin BE, et al. Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial. Acta Oncol 1990; 29: 155-62.
7. 7. Atzpodien J, Kirchner H, Hanninen EL, et al. European studies of interleukin-2 in metastatic renal cell carcinoma. Semin Oncol 1993; 20: 22-6.
8. 8. Fossa SD, de Garis ST, Heier MS, et al. Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma. Cancer 1986; 57: 1700-4.
9. 9. Fossa SD, Martinelli G, Otto U, et al. Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study. Ann Oncol 1992; 3: 301-5.
10. 10. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie [see comments]. N Engl J Med 1998; 338: 1272-8.
11. 11. Schmidinger M, Steger GG, Wenzel C, et al. Sequential administration of interferon-gamma and interleukin-2 in metastatic renal cell carcinoma: results of a phase II trial, submitted.
12. 12. Canobbio L, Boccardo F, Pastorino G, et al. Phase II study of Navelbine in advanced breast cancer. Semin Oncol 1989; 16: 33-6.
13. 13. Cros S, Wright M, Morimoto M, et al. Experimental antitumor activity of Navelbine. Semin Oncol 1989; 16: 15-20.
14. 14. Potier P. The synthesis of Navelbine prototype of a new series of vinblastine derivatives. Semin Oncol 1989; 16: 2-4.
15. 15. WHO. WHO handbook for reporting results of cancer treatment 48. Geneva: WHO Offset Publications 1979.
16. 16. Lee DS, White DE, Rosenberg SA, Yang JC. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy. Cancer J Sci Am 1998; 4: 86-93.
17. 17. Lissoni P, Barni S, Ardizzoia A, et al. Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha. Eur J Cancer 1992; 28: 92-6.
18. 18. Lopez Hanninen E, Poliwoda H, Atzpodien J. Interferon-alpha/5-fluorouracil: a novel outpatient chemo/immunotherapy for progressive metastatic renal cell carcinoma. Cancer Biother 1995; 10: 21-4.
19. 19. Merimsky O, Inbar M, Merimsky E, et al. Phase II study of recombinant interferon alpha-C in patients with metastatic renal cell carcinoma. Mol Biother 1990; 2: 155-9.
20. 20. Lasset C, Merrouche Y, Negrier S, et al. Phase II study of fotemustine as second-line treatment after failure of immunotherapy in metastatic renal cell carcinoma. Cancer Chemother Pharmacol 1993; 32: 329-31.
21. 21. Paolorossi F, Villa S, Barni S, Tancini G, Andres M, Lissoni P. Second-line therapy with interferon-alpha plus vinblastine in metastatic renal cell cancer patients progressed under interleukin-2 subcutaneous immunotherapy. Tumori 1995; 81: 45-7.
22. 22. Palmeri S, Gebbia V, Russo A, Gebbia N, Rausa L. Vinblastine and interferon-alpha-2a regimen in the treatment of metastatic renal cell carcinoma. Tumori 1990; 76: 64-5.
23. 23. Sertoli MR, Brunetti I, Ardizzoni A, et al. Recombinant alpha-2a interferon plus vinblastine in the treatment of metastatic renal cell carcinoma. Am J Clin Oncol 1989; 12: 43-5.
24. 24. Gleave ME, Elhilali M, Fradet Y, et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologie Oncology Group [see comments]. N Engl J Med 1998; 338: 1265-71.